Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Other Non-Current Liabilities (2017 - 2024)

Rhythm Pharmaceuticals (RYTM) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $35.6 million as the latest value for Q2 2024.

  • Quarterly Other Non-Current Liabilities rose 2596.67% to $35.6 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $35.6 million through Jun 2024, up 2596.67% year-over-year, with the annual reading at $1.2 million for FY2023, 14.18% down from the prior year.
  • Other Non-Current Liabilities for Q2 2024 was $35.6 million at Rhythm Pharmaceuticals, up from $660000.0 in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $35.6 million in Q2 2024, with the low at $1000.0 in Q1 2023.
  • Average Other Non-Current Liabilities over 3 years is $4.9 million, with a median of $1.2 million recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities fell 16.98% in 2023, then soared 65900.0% in 2024.
  • Over 3 years, Other Non-Current Liabilities stood at $1.3 million in 2022, then fell by 14.18% to $1.2 million in 2023, then skyrocketed by 2995.3% to $35.6 million in 2024.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $35.6 million, $660000.0, and $1.2 million for Q2 2024, Q1 2024, and Q4 2023 respectively.